Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discusses findings from an analysis of ESR1 variant allele frequencies (VAFs) in patients with estrogen receptor (ER)–positive, HER2-negative, advanced or metastatic ESR1-mutated breast cancer who received elacestrant (Orserdu) or standard of care (SOC) in the phase 3 EMERALD trial (NCT03778931).